INO
What one share of Inovio Pharmaceuticals holds
Pharmaceutical Preparations
Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Annual Report.
Inovio Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.03 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.24 |
| Cash and investments | $0.38 |
| Book value | $0.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.48 | −$1.01 | $0.04 | −$0.89 | — | $1.66 |
| 2017 | $0.52 | −$1.09 | $0.13 | −$0.90 | — | $1.58 |
| 2018 | $0.33 | −$1.05 | $0.02 | −$0.82 | — | $0.89 |
| 2019 | $0.04 | −$1.21 | $0.01 | −$1.00 | — | $0.03 |
| 2020 | $0.05 | −$1.07 | $0.01 | −$1.16 | — | $2.47 |
| 2021 | $0.10 | −$17.45 | $0.07 | −$12.47 | — | — |
| 2022 | $0.52 | −$14.07 | $0.05 | −$10.92 | — | $10.54 |
| 2023 | $0.04 | −$6.09 | $0.01 | −$5.62 | — | $5.15 |
| 2024 | $0.01 | −$3.95 | $0.02 | −$3.85 | — | $1.90 |
| 2025 | $0.00 | −$1.81 | $0.01 | −$1.90 | — | $0.35 |